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Abstract: A ginseng Rb extract (GRbE) containing three major ingredients of ginsenoside Rb1 (G-Rb1), ginsenoside Rb3 
(G-Rb3) and ginsenoside Rd (G-Rd) has been shown to have anticonvulsant and neuroprotective activity. As such, suffi-
cient characterization and standardization of this active GRbE are demanded to facilitate an ongoing preclinical investiga-
tion on its potential for the treatment of epilepsy. In the investigation, the methods for generating the active GRbE and 
isolating G-Rb1, G-Rb3, and G-Rd in large scale from Panax quinquefolius are described. The chemical profile of GRbE 
was characterized by identifying the structure of the individual ingredients using NMR, and the concentration of individ-
ual ingredients was determined using HPLC. This study demonstrates the application of the established methods for re-
producibly generating anticonvulsant GRbE, which is enriched in five panaxadiol glycosides of G-Rb1, ginsenoside Rb2 
(G-Rb2), G-Rb3, ginsenoside Rc (G-Rc), and G-Rd with total ginsenosides over 90%, and for purifying G-Rb1, G-Gb3 and 
G-Rd with purity of 97.9%, 96.6% and 98.6%, respectively.  
Keywords: Anticonvulsant ginseng Rb extract, ginsenosides, preparation, characterization, standardization, Panax  
quinquefolius. 
INTRODUCTION 
Ginseng (Panax L.) has been widely used as tonic and  
restorative agent by Asians for 2,000 years, and is currently a 
component in numerous herbal dietary supplements used 
regularly by about 6 million Americans [1]. More than ten 
species of ginseng reported worldwide are available and used 
as medicinal resources, but the two most commonly used 
species are Panax ginseng C.A. Mey. (Asian ginseng) and 
Panax quinquefolius L. (American ginseng). Both Asian and 
American ginsengs have been cultivated as pharmaceutical 
crops for the production of Standardized Therapeutic  
Extracts (STEs) used in many ginseng products. Although 
some other constituents of ginseng may have some activity, 
it is well known that ginsenosides are the major bioactive 
compounds mainly which are responsible for the effects  
ascribed to ginseng [2]. To date, over 100 ginsenosides have 
been isolated and identified from Panax [3-5], and most of 
them belong to two types of ginsenosides: the panaxadiols 
(e.g., ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2, and Rh3) 
and the panaxatriols (e.g., ginsenosides Re, Rf, Rg1, Rg2, and 
Rh1). Pharmacological effects attributes to ginsenosides have 
been shown in the central nervous system, the cardiovascular 
system, the endocrine system, and the immune system [2].  
Recently, a partially purified ginseng Rb extract (GRbE), 
which is riched in panaxadiol ginsenosides including three 
major ingredients of ginsenoside Rb1 (G-Rb1), ginsenoside  
Rb3 (G-Rb3), and ginsenoside Rd (G-Rd), has shown signifi- 
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cant anticonvulsant effect and neuroprotective activity in 
animal models induced by pilocarpine, kainic acid, 
pentylenetetrazole, and 3-nitropropionic acid [6-8]. 
Interestingly, the activities of this GRbE were stronger than 
those of total ginsenosides (include panaxadiols and 
panaxatriols) and individual panaxadiols. As such, quality 
control of this active GRbE is required to facilitate an 
ongoing preclinical investigation on its potential for the 
treatment of epilepsy. The aim of present study is to develop 
methods for preparing and standardizing the active GRbE 
including the three major ginsenosides G-Rb1, G-Rb3, and G-
Rd from P. quinquefolius. 
MATERIALS AND METHODOLOGY 
Reagents and Materials  
Octadecyl-functionalized silica gel (ODS) and silica gel 
(60-200 mesh, 60Å) were purchased from Sigma-Aldrich 
(St. Louis, MO) and used for column chromatography. Ref-
erence ginsenosides Rb1, Rb2, Rb3, Rc, and Rd were isolated 
by preparative and analytic HPLC from GRbE. The struc-
tures (Fig. 1) of these ginsenosides were determined by ex-
tensive NMR analysis with the purity of 98.5% - 99.3% de-
termined by HPLC and were used as reference compounds. 
All solvents used for extract and column elution (ACS 
grade) and HPLC analysis (HPLC grade) were purchased 
from EMD Chemicals Inc. (Gibbstown, New Jersey).  
Five batches of the roots of P. quinquefolius (American 
ginseng, termed samples AE) were purchased from differ-
ent herbal product stores. Samples A and B were purchased 
from Yan on Ginseng Co. (Houston, USA), samples C and D 
66    Pharmaceutical Crops, 2011, Volume 2 Zhang and Lian 
were obtained from Zhangtongtai Chinese Medicine Phar-
macy (Hangzhou, China), and sample E was purchased from 
Qingshanlu Chinese Medicine Pharmacy (Nanchang, China).  
Apparatus 
NMR experiments were performed on a Bruker 600 MHz 
NMR instrument. HPLC analysis was performed on a Hy-
persil ODS column (column A, 250  4.6 mm, 5 μm, Su-
pelco) using a Hewlett Packard Series 1100 with a HP 1100 
diode array detector. Preparative HPLC was performed with 
an Acuflow Series III pump connected with an Acutect 500 
UV/VIS detector using an Econosil ODS column (column B, 
250  22 mm, 10 μm, Alltech). 
Preparation of Ginseng Rb Extract 
The roots of American ginseng (sample A, 600 g) were 
ground to a coarse powder and percolated with methanol for 
three times (each 4000 mL). Combined methanol solution 
was concentrated under vacuum to give methanol extract 
(60.8 g). This extract was dissolved in 50% methanol (200 
mL) and then chromatographed on a column (600  70 mm) 
of octadecyl-functionalized silica gel (ODS, 1,000 g) eluting 
with 50% and 70% methanol (each, 3,500 mL), respectively. 
Each 70% methanol fraction (200 mL) collected from the 
column was analyzed by HPLC. The fractions 2033 
(4,0006,600 mL) were combined, evaporated under a vac-
uum, and then freeze-dried to give fraction A (11.6 g). Frac-
tion A was further purified using a column (500  45 mm) of 
silica gel (500 g) eluting with chloroform-MeOH (3:1, 1,500 
mL) and then chloroform-MeOH (2:1, 1,500 mL). The chlo-
roform-MeOH (2:1) elution was evaporated under a vacuum 
to give the ginseng Rb extract A (GRbE A, 9.6 g). Using the 
same procedure, GRbE A1 (9.2 g) and GRbE A2 (9.3 g) were 
repeatedly obtained from sample A, and GRbE B (10.8 g), 
GRbE C ( 7.2 g), GRbE D (11.7 g), and GRbE E (7.8 g) 
were generated from the samples BE (each 600 g), respec-
tively. 
Investigation of the Chemical Composition of the Ginseng 
Rb Extract  
The GRbE A (1.0 g) was further separated by preparative 
HPLC using UV detection at 203 nm, flow rate at 5.0 
mL/min and mobile phase of CNCH3/H2O, 40/60) to obtain 
compounds 1 (236 mg, tR 35 min), 2 (38 mg, tR 46 min), a 
mixture of 3 and 4 (490 mg, tR 55 min), and 5 (136 mg, tR 76 
min). The mixture of 3 and 4 was further separated by HPLC 
using a Hypersil ODS column (250  4.6 mm, 5 μm; detec-
tion: 203 nm; flow rate: 1.5 mL/min; flow phase: 
CNCH3/H2O, 32/68) to afford 3 (120 mg, tR 16.1 min) and 4 
(350 mg, tR 18.1 min). 
Structure and Purity Determination of Compounds 15 
The structures of compounds 15 were determined on the 
basis of extensive NMR analysis (1H and 13C NMR, 1H-1H 
COSY, HMQC, and HMBC experiments) and in comparison 
with the reported NMR data [9-11]. The purity of 15 was 
determined by HPLC. 
Isolation and Purification of Individual Ginsenosides Rb1, 
Rb3, and Rd in Large Scale 
GRbE (18.0 g) was dissolved in 50% methanol (100 mL) 
and then applied on a column (600  70 mm) of ODS (1,000 
g) eluting with 5000 mL of 65% methanol. Each fraction 
(100 mL) collected from the column was analyzed by HPLC. 
The fractions containing single compound were combined, 
evaporated under vacuum, and then freeze-dried to give G-
Rb1 (4.12 g, fractions 915, 9001,500 mL), G-Rb3 (3.56 g, 
fractions 2530, 2,5003,000 mL), and G-Rd (2.05 g, frac-
tions 4146, 4,1004,600 mL). 
Preparation of Reference Ginsenosides and Samples Solu-
tion 
Each reference ginsenoside (~5.0 mg) was accurately 
weighted into a 5.0 mL volumetric flask and dissolved in a 
mixture of acetonitrile/water (40:60) to make a stock solu-
tion of 1.0 mg/mL. To create calibration curve, a series of 
work solutions (0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/mL) were 
prepared by diluting the stock solution and filtered through a 
0.2 μm nylon cartridge just prior to HPLC analysis. 
GRbE or individual ginsenoside (~20.0 mg) was accu-
rately weighted into a 100.0 mL volumetric flask and dis-
solved in a mixture of acetonitrile/water (40:60) to make a 
final solution of 0.2 mg/mL. The sample solution was fil-
tered through a 0.2 μm nylon cartridge before HPLC analy-
sis.  
Validation of HPLC Method 
The HPLC method was validated for linearity and repro-
ducibility. The linearity was investigated between peak area 
(y) and the quantity (x, μg) of each component. Five injec-
tions were performed to obtain the absorption plots ranging 
from 0.5 to 5.0μg in five increments. The precision and ac-
curacy of the HPLC method were assessed by within and 
between run validations. The variation was evaluated by 
three injection of a mixture of five reference ginsenosides 
each day on three consecutive days after the preparation of 
reference ginsenoside solution. By substituting the peak area 
into the calibration curve equation from the same run, the 
measured concentrations were obtained. The coefficient of 
variance (RSD%) was calculated by comparing the measured 
concentrations. The relative errors (RE%) were obtained by 
comparing calculated and theoretical concentrations. 
HPLC Analysis 
The separation was carried out on a Hypersil HPLC ODS 
column (250  4.6 mm, 5 μm; detection: 203 nm; flow rate: 
1.5 mL/min; temperature: 25°C). The water was employed as 
 
Fig. (1). Structure of five ginsenosides. 
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mobile phase A, and acetonitrile was employed as mobile 
phase B. The gradient procedure is 036 min with 31–37% 
B, 3637 min with 37% B, 3738 min with 3790% B, 
3842 min with 90% B, 4243 min with 90–31% B, and 
4350 min with 31% B. The injection volume was 10 μL for 
all analytes. Data collection and integration were performed 
using HP ChemStation software.  
RESULTS AND DISCUSSION 
Preparation of Ginseng Rb Extract 
A standard method to generate the anticonvulsant gin-
seng Rb extract from the roots of American ginseng has been 
established in this study. This method allows preparation of 
large amounts of GRbE (about 10.0 g) using column chro-
matography in two steps, first using an ODS column, fol-
lowed by a silica gel column. It is expected that this method 
will produce GRbE in larger scale with commercial value 
when bigger chromatographic columns and larger amount of 
ODS or silica gel are applied.  
The ability to reproducibly generate GRbE from same 
raw material will depend on the conditions of the extract, 
isolation and purification methods such as the ratio of raw 
material weight and solvent volume, the extraction time and 
temperature, the extract solvent, the ratio of loading sample 
and ODS or silica gel, and the eluting solvent. We used a 
standard method developed with the same conditions estab-
lished in this study to prepare three batches of GRbEs AA2 
from the same resource of American ginseng (sample A). As 
shown in Fig. (2) and Table 1, GRbEs AA2 enriched in five 
panaxadiol glycosides of G-Rb1, G-Rc, G-Rb2, G-Rb3, and 
G-Rd with total ginsenosides of over 90%, and had very 
similar ratio of G-Rb1/G-Rc/G-Rb2/G-Rb3/G-Rd as the raw 
material (sample A).  
The ability to reproducibly generate GRbE will also de-
pend, to a significant extent, on the raw material available. 
Previous study [12-14] and our analyses indicate that some 
ginseng products from different sources varied widely in 
content and relative proportions of ginsenosides. Therefore, 
the content and relative proportions of ginsenosides in 
GRbEs prepared from different sources of ginseng products 
may be different. Besides the three batches of GRbEs AA2 
reproducibly prepared from sample A, we had generated 
additional four batches of GRbEs BE from different 
sources (samples BE) using the same method for the prepa-
ration of GRbEs AA2. As shown in Table 1, GRbEs BE 
also contained five panaxadiol glycosides (G-Rb1, G-Rc, G-
Rb2, G-Rb3, and G-Rd) with total ginsenosides of over 90% 
as GRbEs AA2, but the ratios of G-Rb1/G-Rc/G-Rb2/G-
Rb3/G-Rd in GRbEs B-E and GRbEs A-A2 are different. 
This difference is ascribed to the different ratios of G-Rb1/G-
Rc/G-Rb2/G-Rb3/G-Rd in samples AE (Table 1).  
Isolation and Purification of Individual Ginsenosides Rb1, 
Rb3, and Rd in Large Scale 
High-speed counter-current chromatography (HSCCC) 
has been successfully utilized for preparative isolation of G-
Rb1 [15,16] and G-Rd [15] from ginseng plants. HSCCC has 
the advantage of mild separation condition with a 100% re-
covery of the load sample without the solid-phase materials, 
but only a small amount (milligram level) of individual gin-
senoside can be achieved [15,16]. In this study, a simple, 
rapid and convenient column chromatographic method has 
been used and enable to purify three ginsenosides of G-Rb1 
Table 1. Percentage of Total and Individual Ginsenosides (%, Mean ± s.d., n = 3) 
Sample G -Rb1 G –Rc G -Rb2 G -Rb3 G –Rd Total Ratio of 
Rb1/Rc/Rb2/Rb3/Rd 
Sample A 0.48 ± 0.02 0.07 ± 0.01 0.23 ± 0.02 0.68 ± 0.03 0.28 ± 0.01 1.75 ± 0.02 6.9/1.0/3.3/9.7/4.0 
GRbE A 24.62 ± 0.06 3.89 ± 0.02 12.91 ± 0.02 37.25 ± 0.04 13.87 ± 0.07 92.54 ± 0.12 6.3/1.0/3.3/9.6/3.6 
GRbE A1 24.93 ± 0.08 3.68 ± 0.06 12.79 ± 0.05 37.16 ± 0.07 12.69 ± 0.10 91.25 ± 0.36 6.8/1.0/3.5/10.1/3.4 
GRbE A2 24.76 ± 0.08 3.80 ± 0.06 12.80 ± 0.05 37.21 ± 0.07 12.96 ± 0.10 91.53 ± 0.25 6.5/1.0/3.4/9.8/3.4 
Sample B 0.49 ± 0.03 0.08 ± 0.01 0.26 ± 0.01 0.76 ± 0.04 0.27 ± 0.02 1.86 ± 0.03 6.1/1.0/3.3/9.5/3.4 
GRbE B 23.86 ± 0.08 3.90 ± 0.03 12.68 ± 0.03 38.35 ± 0.06 13.16 ± 0.05 91.95 ± 0.26 6.1/1.0/3.3/9.8/3.4 
Sample C 0.53 ± 0.04 0.03 ± 0.01 0.15 ± 0.01 0.28 ± 0.06 0.36± 0.05 1.35 ± 0.05 17.7/1.0/5.0/9.3/12.0 
GRbE C 35.51 ± 0.23 2.08 ± 0.05 10.45 ± 0.12 18.43 ± 0.17 24.59 ± 0.20 91.06 ± 0.19 17.1/1.0/5.2/8.9/11.8 
Sample D 0.70 ± 0.05 0.10 ± 0.01 0.19 ± 0.03 0.76 ± 0.06 0.38 ± 0.05 2.13 ± 0.06 7.0/1.0/1.9/7.6/3.8 
GRbE D 29.67 ± 0.06 4.11 ± 0.02 8.31 ± 0.03 32.23 ± 0.12 16.65 ± 0.06 90.97 ± 0.30 7.2/1.0/2.0/7.8/4.1 
Sample E 0.65 ± 0.03 0.04 ± 0.01 0.12 ± 0.01 0.34 ± 0.02 0.32± 0.02 1.47 ± 0.02 16.3/1.0/3.0/8.5/8.0 
Sample E 39.05 ± 0.11 2.56 ± 0.09 7.89 ± 0.16 22.26 ± 0.13 19.83 ± 0.11 91.60 ± 0.21 15.3/1.0/3.1/8.7/7.7 
G-Rb1 97.9 ± 0.10       
G-Rb3    96.6 ± 0.09    
G-Rd     98.6 ± 0.08   
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(4.12 g), G-Rb3 (3.56 g) and G-Rd (2.05 g) from GRbE using 
an ODS column (600  70 mm). The current work demon-
strates that this method can generate large amounts (gram 
level) of these three compounds, enough for bioactivity stud-
ies, analytic purposes and other uses. Furthermore, the ODS 
column used to generate these three ginsenosides can be re-
peatedly used to reduce the cost.  
HPLC Method Validation 
The HPLC method was validated for linearity and repro-
ducibility. The linearity of the standard curves was studied 
for G-Rb1, G-Rb2, G-Rb3, G-Rc, and G-Rd. The standard 
curve of each ginsenoside was investigated between the peak 
area (y) and the quantity of each ginsenoside (x, μg). The 
linearity is expressed in terms of the correlation coefficient 
(). The correlation coefficient was found to be better than 
0.9999 for each ginsenoside in the range of 0.5 to 5.0 μg. 
The reproducibility of the method was assessed by within 
and between run validations. The RSD% and RE% were 
found to be less than 1.41% and 1.30%, respectively. 
Chemical Profiles of Ginseng Rb Extract (GRbE) 
The chemical profile of GRbE was characterized by de-
fining the chemical constituents and measuring the concen-
tration of total and individual ginsenosides using HPLC. 
Five compounds were isolated and purified from GRbE by 
preparative and analytic HPLC. The structures (Fig. 1) of 
these compounds were determined by extensive NMR spec-
tral analyses as G-Rb1 (1) [9], G-Rc (2) [10], G-Rb2 (3) [11], 
G-Rb3 (4) [10], and G-Rd (5) [9]. Compounds 15 had pu-
rity of 98.5% - 99.3% determined by HPLC and were used 
as reference compounds.  
The established HPLC method was used to determine the 
chemical constituents and quantitate the concentration of 
total and individual ginsenosides of GRbEs AE. As shown 
in Fig. (2) and Table 1, the seven batches of GRbEs AE 
prepared in this study contain the same chemical constitu-
ents: G-Rb1 (tR: 10.7 min), G-Rc (tR: 13.0 min), G-Rb2 (tR: 
15.8 min), G-Rb3 (tR: 16.7 min), and G-Rd (tR: 22.8 min), 
and the total ginsenosides for each individual preparations is 
over 90%. 
CONCLUSION 
A standardized method to prepare the anticonvulsant 
GRbE from different American ginseng resources by a com-
bination of ODS and silica gel open column chromatography 
has been established. The structures of the individual ginse-
nosides from GRbE were confirmed by extensive NMR 
analysis. A validated HPLC method was used to verify the 
chemical constituents and to determine the concentration of 
total and individual ginsenosides of GRbE. This study dem-
onstrates the application of the established methods for re-
producibly generating a standardized anticonvulsant GRbE. 
This active GRbE concentrated five panaxadiol ginsenosides 
of Rb1, Rb2, Rb3, Rc, and Rd with total ginsenosides over 
90%, and meet the requirement for an ongoing preclinical 
investigation on its potential for the treatment of epilepsy.  
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ABBREVIATIONS 
G-Rb1 = Ginsenoside Rb1 
G-Rb2 = Ginsenoside Rb2 
G-Rb3 = Ginsenoside Rb3 
G-Rc = Ginsenoside Rc 
G-Rd = Ginsenoside Rd 
GRbE = Ginseng Rb extract  
HSCCC = High-speed counter-current chromatogra-
phy 
REFERENCES 
[1] Kuhn, M.A.; Winston, D. Herbal therapy and supplements: a scien-
tific and traditional approach. Lippincott: New York, 2000. 
[2] Attele, A.S.; Wu, J.A.; Yuan, C.S. Ginseng pharmacology: multiple 
constituents and multiple actions. Biochem. Pharmacol., 1999, 
58(11), 1685-1693.  
[3] Zhu, S.; Zou, K.; Cai, S.Q.; Meselhy, M.R.; Komatsu, K. Simulta-
neous determination of triterpene saponins in ginseng drugs by 
high-performance liquid chromatography. Chem. Pharm. Bull., 
2004, 52(8), 995-998. 
[4] Banskota, A.H.; Tezuka, Y.; Le Tran, Q.; Kadota, S. Chemical 
constituents and biological activities of Vietnamese medicinal 
plants. Curr. Top. Med. Chem., 2003, 3(2), 227-248. 
[5] Zou, K.; Zhu, S.; Meselhy, M. R.; Tohda, C.; Cai, S.Q.; Komatsu 
K. Dammarane-type saponins from Panax japonicus and their neu-
rite outgrowth activity in SK-N-SH cell. J. Nat. Prod., 2002, 65(9), 
1288-1292. 
[6] Lian, X.Y.; Zhang, Z.Z.; Stringer, J.L. Anticonvulsant activity of 
ginseng on seizures induced by chemical convulsants. Epilepsia, 
2005, 46(1), 15-22. 
[7] Lian, X.Y.; Zhang, Z.Z.; Stringer, J.L. Anticonvulsant and neuro-
protective effects of ginsenosides in rats. Epilepsy Res., 2006, 70(2-
3), 244-256.  
[8] Lian, X.Y.; Zhang, Z.Z.; Stringer, J.L. Protective effects of ginseng 
components in a rodent model of neurodegeneration. Ann. Neurol., 
2005, 57(5), 642-648. 
[9] Dong, A.; Ye, M. Guo, H.; Zheng, J.; Guo, D. Microbial transfor-
mation of ginsenoside Rb1 by Rhizopus stolonifer and Curvularia 
lunata. Biotechnol. Lett., 2003, 25(4), 339-344. 
[10] Liu, C., Han, J., Quan, Y.; Huang, X.; Wang, H. Purification and 
quantification of ginsenosides Rb3 and Rc from crude extracts of 
caudexes and leaves of Panax notoginseng. Sep. Purif. Technol., 
2007, 54, 198-203. 
[11] Tanaka, O.; Kasai, R. In: Herz, W.; Grisebach, H.; Kirby, G.W.; 
Tamm C, Eds. Progress in the Chemistry of Organic Natural Prod-
ucts. SpringerVerlag, WienNew York, 1984, Vol. 46, pp. 1-76. 
[12] Cui, J.; Garle, M.; Eneroth, P.; Björkhem, I. What do commercial 
ginseng preparations contain? Lancet, 1994, 344(8915), 134. 
[13] Harkey, M.R.; Henderson, G.L.; Gershwin, M.E.; Stern, J.S.; 
Hackman, R.M. Variability in commercial ginseng products: an 
analysis of 25 preparations. Am. J. Clin. Nutr., 2001, 73(6), 1101-
1106. 
[14] Li, W.; Fitzloff, J.F. HPLC determination of ginsenosides content 
in ginseng dietary supplements using ultraviolet detection. J. Liq. 
Chromatogr. R. T., 2002, 25(16), 2485-2500. 
[15] Cao, X.L.; Tian, Y.; Zhang, T.Y.; Liu, Q.H.; Jia, L.J.; Ito, Y. Sepa-
ration of dammarane-saponins from notoginseng, root of Panax no-
toginseng (Burk.) F.H. Chen, by HSCCC coupled with evaporative 
light scattering detector. J. Liq. Chromatogr. R. T., 2003, 26(9-10), 
1579-1591. 
 [16] Du, Q.; Jerz, G.; Waibel, R.; Winterhalter, P. Isolation of damma-
rane saponins from Panax notoginseng by high-speed counter-
current chromatography. J. Chromatogr. A., 2003, 1008(2), 173-
180. 
 
Received: June 16, 2011 Revised: July 15, 2011 Accepted: July 19, 2011 
 
© Zhang and Lian; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/ by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
